Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect resulting from enhanced tumor-infiltrating DCs and macrophage infiltrate switching from M2 to M1 consequently produce increased IL-12 and tumor necrosis factor (TNF) (76).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intratumor injections of TLR9 ligand CpG and anti-IL10R antibody are able to reinforce antitumor efficacy in C26 and B16 animal models.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“Although the main function of dendritic cells (DCs) * is probably to orchestrate a defense against pathogens, DCs are also well equipped to initiate antitumor responses (1).”
BackgroundA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“We tested different combinations of substances with the aim of relieving tumor-mediated inhibition and simultaneously mediating DC activation, including combinations of the TLR-9 ligand CpG 1668 (21) and an anti–IL-10R blocking antibody (15).”
MethodMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291 · cited 4×
“In contrast, TIDCs from X/myc hepatocarcinoma were representative of distinct subsets of mouse DCs (19).”
BackgroundResultInfluentialKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“Indeed, it was recently reported that immature DC injection would induce antigen-specific T cell unresponsiveness in man (22).”
BackgroundMayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022 · cited 1×
“On the other hand, TIDCs isolated from liver hepatocarcinoma were more diverse, including CD11b and CD11b DCs as well as cells expressing CD8 an/or B220, the latter marker being ascribed to mouse type I IFN-producing cells (19, 20).”
BackgroundSelf-citationZou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · cited 1×
“Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Self-citation
Cited by
Items 101–200 of 351
Lu, H., Wagner, W. M., Gad, E. A., Yang, Y., Duan, H., Amon, L. M., Denend, N. V., Larson, E. R., Chang, A., Tufvesson, H., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902997 · Cited by 87
“Interestingly, it has been shown that the TLR-9 agonist CpG can also induce IL-10, potentially via activation of p38 MAPK, and IL-10 blockade, or inhibiting the p38 MAPK signaling in DC can augment the antitumor effect of CpG (45, 46).”
BackgroundMacrophages heterogeneity in atherosclerosis – implications for therapy
Wilson, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01121.x · Cited by 95
“Tumours, like pathogens, can skew macrophage functions by reducing their ability to produce IL-12 while enhancing autocrine IL-10 production [86] and by decreasing their antigen presenting ability.”
BackgroundAugier, S., Ciucci, T., Luci, C., Carle, G. F., Blin-Wakkach, C., & Wakkach, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902583 · Cited by 79
“Supporting these observations, recent studies have demonstrated that CpG plus anti–IL-10R Ab treatment induced robust antitumor therapeutic activity (15, 43).”
BackgroundVaccination for Treatment and Prevention of Cancer in Animal Models
Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G., & Melief, C. J. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90005-4 · Cited by 86
Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination
Benencia, F., Sprague, L., McGinty, J., Pate, M., & Muccioli, M. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/425476 · Cited by 81
Schüler, T., & Blankenstein, T. J. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4427 · Cited by 82
Valvis, S. M., Waithman, J. C., Wood, F. M., Fear, M. W., & Fear, V. S. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.123 · Cited by 80
Immunostimulatory combinations: designing the next generation of vaccine adjuvants
Kornbluth, R. S., & Stone, G. W. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306147 · Cited by 78
“[288] found that TLR agonists can be combined with agents that block inhibitors of DC activation.”
BackgroundEnhancement of Infectious Disease Vaccines Through TLR9-Dependent Recognition of CpG DNA
McCluskie, M. J., & KRIEG, A. M. (2006) · Springer eBooks · doi:10.1007/3-540-32636-7_6 · Cited by 79
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Self-citationRoux, S., Apétoh, L., Chalmin, F., Ladoire, S., Mignot, G., Puig, P., Lauvau, G. S., Zitvogel, L., Martin, F., Chauffert, B., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35890 · Cited by 84
Tumor Antigen Cross‐Presentation and the Dendritic Cell: Where it All Begins?
McDonnell, A. M., Robinson, B. W. S., & Currie, A. J. (2010) · Journal of Immunology Research · doi:10.1155/2010/539519 · Cited by 88
“Such signals include pathogen-associated molecular patterns (PAMPs), derived from bacterial and viral infection, such as LPS and unmethylated CpG motifs that are recognized by specific receptors on DCs, including TLRs. Likewise, CD40CD40 ligand (CD154) interaction with activated CD4+ T cells can result in DC activatio…”
ResultA model for cancer-suppressive inflammation
Haabeth, O. A. W., Bogen, B., & Corthay, A. (2012) · OncoImmunology · doi:10.4161/onci.21542 · Cited by 81
De, A. K., Laudański, K., & Miller‐Graziano, C. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6355 · Cited by 75
“4 GM-induced M -to-DC differentiation can be altered by numerous microenvironmental changes (28).”
BackgroundBaird, J. R., Bell, R. B., Troesch, V., Friedman, D. J., Bambina, S., Kramer, G. F., Blair, T. C., Medler, T. R., Wu, Y., Sun, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1652 · Cited by 75
Vollmer, J. (2006) · International Reviews of Immunology · doi:10.1080/08830180600743107 · Cited by 73
Stone, G. W., Barzee, S., Snarsky, V., Santucci, C., Tran, B., Langer, R., Zugates, G. T., Anderson, D. G., & Kornbluth, R. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007334 · Cited by 78
“combined intratumoral CpG injections with systemic anti-IL10R antibody leading to the eradication of established B16F10 melanoma [4], an effect that depended upon endogenous CD40L [73].”
Melzer, M., Lopez-Martinez, A., & Altomonte, J. (2017) · Biomedicines · doi:10.3390/biomedicines5010008 · Cited by 78
“Colon carcinoma, mastocytoma, Lewis lung carcinoma and B16 melanoma models have additionally demonstrated increased percentages of immature mDCs [46].”
BackgroundRecent advances in the development of immunostimulatory oligonucleotides.
Uhlmann, E., & Vollmer, J. (2003) · PubMed · Cited by 71
Dercamp, C., Chemin, K., Caux, C., Trinchieri, G., & Vicari, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1319 · Cited by 70
“Activation consisted of 5 Ag/mL of CpG 1668 F 10 Ag/mL anti-IL-10R antibody.”
BackgroundMethodSelf-citationStrategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 67
“Others have reported that immature tumor-infiltrating DC isolated from B16-F0 tumors are refractory to ex vivo stimulation with a cocktail of maturation stimuli but can be induced to undergo maturation following stimulation in the presence of an anti-IL-10R neutralizing antibody (112).”
BackgroundManipulating IL-10 signalling blockade for better immunotherapy
Ni, G., Wang, T., Walton, S. F., Zhu, B., Chen, S., Wu, X., Wang, Y., Wei, M. Q., & Liu, X. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.012 · Cited by 71
Taneichi, M., Ishida, H., Kajino, K., Ogasawara, K., Tanaka, Y., Kasai, M., Mori, M., Nishida, M., Yamamura, H., Mizuguchi, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2324 · Cited by 76
“It has been reported that CpG and anti-IL-10 receptor Ab reverse tumor-induced DC paralysis, resulting in tumor rejection by CTL activated by the DC (38).”
BackgroundMoreira, D., Zhang, Q., Hossain, D. M. S., Nechaev, S., Li, H., Kowolik, C. M., D’Apuzzo, M., Forman, S., Jones, J., Pal, S. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4029 · Cited by 62
“STAT3 is an essential negative feedback inhibitor for TLR9 signaling which is activated by NF-κB-induced cytokines such as IL-6 or IL-10 [9, 13, 14].”
BackgroundShimabukuro‐Vornhagen, A., Draube, A., Liebig, T. M., Rothe, A., Kochanek, M., & von Bergwelt‐Baildon, M. S. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-47 · Cited by 68
“Consequently, inhibition of TGF-β, IL-10, or VEGF signaling improves DC function and enhances the efficacy of tumor vaccines [47–49].”
Becker, Y. (2006) · PubMed · Cited by 65
Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer
Wang, R. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.009 · Cited by 65
Probiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Wang, Q., Cheng, F., Ma, T., Xiong, H.-Y., Li, Z., Xie, C.-L., Liu, C., & Tu, Z. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2687-0 · Cited by 66
Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities
Connerotte, T., Pel, A. V., Godelaine, D., Tartour, É., Schuler‐Thurner, B., Lucas, S., Thielemans, K., Schuler, G., & Coulie, P. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5898 · Cited by 67
“In doing so, it mayhowever promote viral persistence (38) or inhibit antitumor immunity( 39 ).”
BackgroundSabado, R. L., & Bhardwaj, N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12125 · Cited by 64
Bos, R., van Duikeren, S., Morreau, H. M., Franken, K. L. M. C., Schumacher, T. N., Haanen, J. B. A. G., van der Burg, S. H., Melief, C. J. M., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1864 · Cited by 60
“In addition to 4.5 Gy TBI, we suppressed the action of the key regulatory cytokine IL-10 (21) by injecting IL-10R blocking antibodies ( 22 ).”
MethodInfluentialTargeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task
Ni, G., Zhang, L., Yang, X., Li, H., Ma, B., Walton, S. F., Wu, X., Yuan, J., Wang, T., & Liu, X. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1717185 · Cited by 64
Chen, Y., Lin, C.-W., Tsao, Y., & Chen, S. (2004) · Journal of Virology · doi:10.1128/jvi.78.3.1333-1343.2004 · Cited by 60
“To determine the relative roles of CD4 and CD8 T cells in E5 peptide-based vaccine protection against tumors, mice deficient in CD4 and CD8 T cells as a result of targeted gene disruption at 2m and MHC-II, respectively, were studied.”
BackgroundInfluentialRutkowski, M. R., Svoronos, N., Perales‐Puchalt, A., & Conejo-Garcia, J. R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.011 · Cited by 64
“…of TNFα during intratumoral immunotherapy with CpG-oligodeoxynucleotides (CpG-ODN) and inhibition of IL-10 signaling (Iida et al., 2013), an immunotherapeutic combination that has been shown to reverse dendritic cell immune suppression within the tumor microenvironment (Vicari et al., 2002).”
BackgroundCruz, L. J., Tacken, P. J., Eich, C., Rueda, F., Torensma, R., & Figdor, C. G. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0295 · Cited by 58
The Impact of the Myeloid Response to Radiation Therapy
Gough, M. J., Young, K. H., & Crittenden, M. R. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/281958 · Cited by 58
Burocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., & Piconese, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201141700 · Cited by 54
Self-citationImmunotherapeutic modulation of the suppressive liver and tumor microenvironments
Chan, T., Wiltrout, R. H., & Weiss, J. M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.024 · Cited by 57
“In addition, the removal of the DC-derived immunosuppressive IL-10 may further improve the immunostimulatory capacity of DC-based therapies (48-50).”
BackgroundRegulatory T cells and Toll-like receptors in tumor immunity
Wang, R., Peng, G., & Wang, H. Y. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.01.008 · Cited by 59
The immune escape in melanoma: role of the impaired dendritic cell function
Tucci, M., Stucci, L. S., Passarelli, A. M., Giudice, G., Dammacco, F., & Silvestris, F. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.955851 · Cited by 55
“In particular, inhibition of the IL-10 receptor does indeed enhance CpGinduced anti-tumor immunity [69], while a similar effect was obtained by restraining JAK-STAT signaling, inducing an improvement of the DC-based vaccine response in melanoma models [54].”
BackgroundTargeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect
Suek, N., Campesato, L. F., Merghoub, T., & Khalil, D. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00604 · Cited by 55
“Upon treatment with CpG and IL10R blocking antibody to activate TIDCs, tumors were regressed by an adaptive immune response (6).”
BackgroundMethodMetabolic regulation on the immune environment of glioma through gut microbiota
Lyu, Y., Yang, H., & Liang, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.005 · Cited by 58
Vas, J., Grönwall, C., Marshak‐Rothstein, A., & Silverman, G. J. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34537 · Cited by 55
“Alternatively, type B phosphorothioate CpG-containing oligodeoxynucleotide (CpG ODN) 1668 (5 -TCCATGACGTTCCTGACGTT-3 ; Bioneer) (16) was used as a TLR-9 agonist in some experiments.”
Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Naive Dendritic Cells
Song, W., & Levy, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0406 · Cited by 57
Mumm, J. B., & Oft, M. (2013) · BioEssays · doi:10.1002/bies.201300004 · Cited by 53
Höpken, U. E., Lehmann, I., Droese, J., Lipp, M., Schüler, T., & Rehm, A. (2005) · European Journal of Immunology · doi:10.1002/eji.200526298 · Cited by 65
Chang, W. L. W., Baumgarth, N., Eberhardt, M. K., Lee, C. Y. D., Baron, C. A., Gregg, J. P., & Barry, P. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7794 · Cited by 61
“IL-10 are found in many cancer patients (11).”
BackgroundStimulating Innate Immunity to Enhance Radiation Therapy–Induced Tumor Control
Baird, J. R., Monjazeb, A. M., Shah, O., McGee, H. M., Murphy, W. J., Crittenden, M. R., & Gough, M. J. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.04.014 · Cited by 53
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 58
Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines
Vicari, A. P., Treilleux, I., & Lebecque, S. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.002 · Cited by 51
Self-citationKuhn, S. P., Hyde, E. J., Yang, J., Rich, F. J., Harper, J. L., Kirman, J. R., & Ronchese, F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301135 · Cited by 49
IL‐10 induces MC3T3‐E1 cells differentiation towards osteoblastic fate in murine model
Xiong, Y., Yan, C., Chen, L., Endo, Y., Sun, Y. T., Zhou, W., Hu, Y., Hu, L., Chen, D., Xue, H., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14832 · Cited by 52
Antigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells
Gerner, M. Y., & Mescher, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803479 · Cited by 58
“Phenotypic examination of TIDC showed that they were largely indistinguishable from normal interstitial dermal DC, which is in agreement with other data that have described a large prevalence of CD11b DC infiltrating various murine tumors (36, 51).”
BackgroundResultReversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Tabana, Y., Moon, T. C., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937123 · Cited by 50
“In addition, combining intra-tumor injection of Toll-like receptor 9 ligand, CpG, with an anti-IL-10 mAb significantly increases the anti-tumor efficacy [153].”
MethodRecruitment and Differentiation of Conventional Dendritic Cell Precursors in Tumors
Diao, J., Zhao, J., Winter, E., & Cattral, M. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0903050 · Cited by 48
“Our results conflict with a previous study showing that tumor DC are paralyzed and resistant tomaturation (5).”
BackgroundResultMolavi, O., Mahmud, A., Hamdy, S. I., Hung, R., Lai, R. L., Samuel, J., & Lavasanifar, A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900145g · Cited by 49
Rallis, K. S., Corrigan, A. E., Dadah, H., Stanislovas, J., Zamani, P., Makker, S., Szabados, B. E., & Sideris, M. C. (2022) · Future Oncology · doi:10.2217/fon-2022-0063 · Cited by 50
Nakamoto, Y., Mizukoshi, E., Tsuji, H., Sakai, Y., Kitahara, M., Kazumori, A. R. A. I., Yamashita, T., Yokoyama, K., Mukaida, N., Matsushima, K., et al. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03290.x · Cited by 46
T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Dennis, K. L., Saadalla, A., Blatner, N. R., Wang, S., Venkateswaran, V., Gounari, F., Cheroutre, H., Weaver, C. T., Roers, A., Egilmez, N. K., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0169 · Cited by 45
Localized Multi‐Component Delivery Platform Generates Local and Systemic Anti‐Tumor Immunity
Acharya, A. P., Sinha, M. K., Ratay, M. L., Ding, X., Balmert, S. C., Workman, C. J., Wang, Y., Vignali, D. A. A., & Little, S. R. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201604366 · Cited by 46
Zotta, A., Toller-Kawahisa, J. E., Pålsson‐McDermott, E. M., O’Carroll, S. M., Henry, Ó. C., Day, E. A., McGettrick, A. F., Ward, R. W., Ryan, D. G., Watson, M. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq7307 · Cited by 45
“We therefore tested S3QEL 1.2 in the B16F10 melanoma in vivo model, where neutralization of the IL-10 receptor with an antibody has been shown to boost antitumor immunity, especially in combination with CpG DNA ( 36 ).”
InfluentialGorczynski, R., Khatri, I. A., Lee, L., & Boudakov, I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5946 · Cited by 45
“Combination treatment with CpG anti-IL-10R modifies functional activity in DCs (53).”
BackgroundType I Regulatory T Cells in Autoimmunity and Inflammatory Diseases
Veldman, C. M., Nagel, A. K., & Hertl, M. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000092576 · Cited by 48
The role of dendritic cells in cancer immunity and therapeutic strategies
Tai, Y., Chen, M., Wang, F., Fan, Y., Zhang, J., Cai, B., Lin, Y., Luo, Y., & Li, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111548 · Cited by 45
The tumour microenvironment and implications for cancer immunotherapy
Petrulio, C., Kim‐Schulze, S., & Kaufman, H. L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.7.671 · Cited by 44
“The combination of CpG and anti–IL-10R therapy enhanced TAA-specific immune response and triggered de novo IL-12 production from TADCs in mice [85].”
BackgroundAtaera, H., Hyde, E. J., Price, K. M., Stoitzner, P., & Ronchese, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017515 · Cited by 46
“range of inhibitory mechanisms such as decreased inflammatory cytokines, increased anti-inflammatory cytokines [14,15] and increased Treg infiltration [16,17], which are likely to affect the function of local T cells [18] as well as DC [7].”
BackgroundPhenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
Lee, G. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/5458178 · Cited by 52
The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer
Li, Y., Wang, J., Wang, H., Zhang, S., Wei, Y., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850093 · Cited by 49
“IL-10 also suppresses tumor-infiltrating DC maturation and their production of IL-12 to stimulate Th1 cells (37).”
BackgroundCancer Immunity: Lessons From Infectious Diseases
Trinchieri, G. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv070 · Cited by 46
“TGF-β are neutralized [30–32].”
Self-citationMocellin, S., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 47
Functional control of regulatory T cells and cancer immunotherapy
Wang, R. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.004 · Cited by 44
Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment
Lotfi, R., Kaltenmeier, C., Lotze, M. T., & Bergmann, C. (2016) · Transfusion Medicine and Hemotherapy · doi:10.1159/000444941 · Cited by 48
Is it true that gut microbiota is considered as panacea in cancer therapy?
Farrokhi, A. S., Darabi, N., Yousefi, B., Askandar, R. H., Shariati, M., & Eslami, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28333 · Cited by 45
“Administration of CpG‐ODN in combination with anti‐IL‐10 antibodies (anti‐IL‐10 ab) in tumor tissue could be more effective against transplantable tumors (Vicari et al., 2002).”
BackgroundBiollaz, G., Bernasconi, L., Cretton, C., Püntener, U., Frei, K., Fontana, A., & Suter, T. B. (2009) · European Journal of Immunology · doi:10.1002/eji.200838921 · Cited by 44
Johnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 43
Gray, R. C., Kuchtey, J., & Harding, C. V. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1006606 · Cited by 40
“ODNs were provided by Coley Pharmaceutical Group, purchased from InvivoGen (San Diego, CA, USA), or were described elsewhere [22, 23] and synthesized by MWG-Biotech (High”
MethodMyeloid Cells as Targets for Therapy in Solid Tumors
Cotechini, T., Medler, T. R., & Coussens, L. M. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000132 · Cited by 39
Larmonier, N., Cathelin, D., Larmonier, C. B., Nicolas, A., Mérino, D., Janikashvili, N., Audia, S., Bateman, A., Thompson, J., Kottke, T., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.03.027 · Cited by 40
Molavi, O., Ma, Z., Hamdy, S. I., Lai, R. L., Lavasanifar, A., & Samuel, J. (2008) · Immunology and Cell Biology · doi:10.1038/icb.2008.27 · Cited by 39
Mills, K. H. G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.11.007 · Cited by 39
Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer
Sanaei, M., Salimzadeh, L., & Bagheri, N. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ru0819-150rr · Cited by 39
Guiducci, C., Carlo, E. D., Parenza, M., Hitt, M., Giovarelli, M., Musiani, P., & Colombo, M. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4026 · Cited by 41
“In this context, strategies aimed at neutralizing IL-10 in the TSA model (65) or TGF- in the 4T1 model have led to the functional restoration of tumor-infiltrating APC (66).”
BackgroundSelf-citationNi, G., Wang, Y., Wu, X., Wang, X., Chen, S., & Liu, X. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.10.001 · Cited by 38
Current strategies in engaging oncolytic viruses with antitumor immunity
Boagni, D., Ravirala, D., & Zhang, S. X. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.002 · Cited by 39
Ishii, K. J., Kawakami, K., Gürsel, İ., Conover, J., Joshi, B. H., Klinman, D. M., & Puri, R. K. (2003) · PubMed · Cited by 37
Kariagina, A., & Doseff, A. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415753 · Cited by 39
“In addition, impaired DC function was reversed by antibodies against IL-10 combined with immunostimulatory oligonucleotide CpG [174].”
BackgroundTian, H., Shi, G., Yang, G., Zhang, J., Li, Y., Du, T., Wang, J., Xu, F., Cheng, L., Zhang, X., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-48 · Cited by 36
RetractedThe Tumor Microenvironment: Part 1
Leibovici, J., Itzhaki, O., Huszar, M., & Sinai, J. (2011) · Immunotherapy · doi:10.2217/imt.11.111 · Cited by 39
Tesone, A. J., Svoronos, N., Allegrezza, M. J., & Conejo-Garcia, J. R. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00435 · Cited by 36
“They found that DCs were refractory to stimulation with the combination of LPS, IFN-γ, and anti-CD40 antibody, but tumor-induced DC paralysis could be reverted by a combination of CpGs and an anti-IL-10R antibody (108).”
BackgroundThe therapeutic value of targeting inflammation in gastrointestinal cancers
Sun, B., & Karin, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.011 · Cited by 37
“Moreover, the combination of CpG immunostimulatory oligonucleotide plus an anti-IL-10 receptor antibody switches the infiltrating TAMs from the M2 to the M1 phenotype, which can promote tumor rejection, represents another sophisticated strategy for cancer treatment [50].”
BackgroundRouas, R., Merimi, M., Najar, M., Zein, N. E., Fayyad‐Kazan, M., Berehab, M., Agha, D. M., Bron, D., Burny, A., Rachidi, W., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28367 · Cited by 36
“increased rejection of organ transplantation (Vicari et al., 2002).”
BackgroundBiological Insight and Recent Advancement in the Treatment of Neuroblastoma
Rivera, Z., Escutia, C., Madonna, M. B., & Gupta, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108470 · Cited by 36
“Studies carried out in different tumor models have demonstrated that blocking the IL-10R relieves immunosuppression in the tumor microenvironment and reinstates immune response directed at malignant cells [83].”
BackgroundPhysiological Role of Plasmacytoid Dendritic Cells and Their Potential Use in Cancer Immunity
Schettini, J. L., & Mukherjee, P. (2008) · Clinical and Developmental Immunology · doi:10.1155/2008/106321 · Cited by 32
“Nevertheless, using an anti-IL10 mAb and CpG ODN, it is possible to induce a robust antitumor CTL response and tumor rejection in vivo [111].”
MethodSprague, L., Muccioli, M., Pate, M., Singh, M., Xiong, C., Ostermann, A. O., Niese, B., Li, Y., Li, Y., Courreges, M. C., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.01.031 · Cited by 31
“Indeed, it has been reported that tumorassociated DCs are often not capable of engaging in productive immune response, suffering what is defined as an “immune paralysis” [117].”
BackgroundSprague, L., Muccioli, M., Pate, M., Meles, E., McGinty, J. W., Nandigam, H., Venkatesh, A., Gu, M.-Y., Mansfield, K., Rutowski, A., et al. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-35 · Cited by 37
“Furthermore, treatment of the tolerogenic DCs with inflammatory molecules, render immunogenic DCs with the capability to activate T cells [11].”
BackgroundSaegusa, K., Yotsumoto, S., Kato, S., & Aramaki, Y. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.008 · Cited by 30
Rovere, P. Q., & Manfredi, A. A. (2004) · PubMed · Cited by 29
Cytokines in Neuroblastoma: From Pathogenesis to Treatment
Pistoia, V., Bianchi, G., Borgonovo, G., & Raffaghello, L. (2011) · Immunotherapy · doi:10.2217/imt.11.80 · Cited by 31
Chen, Z., Xia, D., Bi, X., Saxena, A., Sidhu, N., El-Gayed, A. A. H., & Xiang, J. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.692 · Cited by 31
“On the other hand, a couple of reports demonstrated that, although DCs are found to exist within solid tumors, DCs from tumor-bearing patients are immature or have impaired presentation abilities [24,25].”
Background
Metadata
- Authors
- Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
- Affiliations
- 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Inserm (FR)
- 4DNAX Research Institute, Palo Alto, CA 94304
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-19
- Volume
- 196
- Issue
- 4
- Pages
- 541-549
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2196048
- OpenAlex
- W2156592930
- Cited by
- 343
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.